"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
| Descriptor ID |
D002316
|
| MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
| Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 4 | 2 | 6 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 1 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence? Drugs. 2023 Feb; 83(3):195-201.
-
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin. 2022 Nov; 38(11):1785-1795.
-
Effect of Phenylephrine Push Before Continuous Infusion Norepinephrine in Patients With Septic Shock. Chest. 2021 05; 159(5):1875-1883.
-
Old Drug, New Trick? Oral Milrinone for Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2020 07 07; 9(13):e017170.
-
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.
-
Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. J Clin Pharmacol. 2019 12; 59(12):1606-1619.
-
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
-
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Circulation. 2019 08 20; 140(8):e333-e381.
-
Nrf2 expression and function, but not MT expression, is indispensable for sulforaphane-mediated protection against intermittent hypoxia-induced cardiomyopathy in mice. Redox Biol. 2018 10; 19:11-21.
-
Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of?Heart Failure. JACC Heart Fail. 2018 07; 6(7):564-569.